PB MRD assessments over time. On the x-axis, the different time points when MRD was assessed as per protocol are shown; on the y-axis, the MRD value expressed as percentage of leukocytes is shown. (A) Patients treated with venetoclax only. (B) Patients treated with venetoclax monotherapy followed by venetoclax combined with ibrutinib until uMRD4, progressive disease, unacceptable toxicity, or Cycle 24 Day 28, whichever occurs first. Two patients (highlighted in red) had uMRD4 in PB at Cycle 12 Day 1 assessment but were MRD⁺ in the BM, thus fulfilling per protocol MRD⁺ criteria. IBR, ibrutinib; VEN, venetoclax.